CAR T cell News and Research

RSS

EMA recognizes the value of EBMT patient registry for novel CAR T-cell therapies

CAR T-cell immunotherapies are advanced therapy medicinal products manufactured from human primary living cells procured by hospitals or blood banks.

4 Mar 2019

Moffitt researchers shed light on how CAR T cells function mechanistically

The scientific community has made great strides over the past decade in the development of a new class of cancer therapy called immunotherapy, a treatment that activates a patient's own immune system to target cancer cells.

15 Feb 2019

New mouse model replicates development and progression of Type I diabetes

Researchers at The University of Toledo have found a new way to replicate in lab mice the development and progression of Type I diabetes, a breakthrough that has the potential to reshape how the chronic disease is studied.

13 Feb 2019

NETRF announces $2.5 million funding for neuroendocrine cancer research

The Neuroendocrine Tumor Research Foundation continues its aggressive funding of neuroendocrine cancer research with eight new grants totaling $2.5 million.

7 Feb 2019

UCLA researchers demonstrate new technique to develop cancer-fighting T cells

A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells -- which can give rise to every cell type in the body and which can be grown indefinitely in the lab -- into becoming mature T cells capable of killing tumor cells.

18 Jan 2019

Quanterix extends oncology footprint with accelerated launch of next gen SP-X platform and CorPlex validated 10-Plex

Quanterix announce launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels.

From Quanterix 10 Jan 2019

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

Physician-scientists present updated efficacy data on CAR T-cell gene immunotherapy

Physician-scientists from Children's Hospital of Philadelphia presented updated efficacy and safety data on Kymriah--the first-ever U.S. Food and Drug Administration approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the 60th American Society of Hematology annual meeting, as well as first-of-its-kind research on overcoming CAR T-cell resistance.

5 Dec 2018

CAR-T cell therapy appears to be promising option for treating large B-cell lymphoma

So-called CAR-T cell therapy is a promising option for treating around a fifth of patients with diffuse large B-cell lymphoma.

4 Dec 2018

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy Yescarta remained in remission more than two years following therapy, and more than half of the patients treated remain alive.

4 Dec 2018

New strategies may improve performance of CAR-T cell therapy in treating cancer

Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

3 Dec 2018

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

Chimeric antigen receptor T-cell therapy, or CAR T, was named the 2017 Advance of the Year by the American Society of Clinical Oncology. The FDA approved two CAR T products last year for treatment of adult large B-cell lymphoma based on the exceptional patient outcomes seen in clinical trials.

3 Dec 2018

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.

3 Dec 2018

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

3 Dec 2018

First-ever European Meeting on CAR T Cell Therapy represents educational opportunity for healthcare professionals

CAR T Cell Therapy is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases.

29 Nov 2018

New study sheds light on how CAR T cell therapy works

Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly 610,000 people expected to die from the disease, according to the National Cancer Institute.

8 Nov 2018

TGen and City of Hope announce letter of intent to develop new cell therapy manufacturing facility

City of Hope, a world-renowned independent cancer research and treatment center, and its affiliate, Translational Genomics Research Institute, have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered.

5 Nov 2018

Cytek Biosciences introduces new Northern Lights series of advanced flow cytometry systems

The door to discovery has been opened, and the traditional flow cytometry market is set to see a paradigm shift. With its new Northern Lights series of advanced flow cytometry systems, Cytek Biosciences Inc. is making three lasers and more than 24 colors possible at a price point typically attached to systems with far fewer capabilities.

From Cytek Biosciences 2 Nov 2018

TGen, City of Hope to develop cell therapy manufacturing facility in Phoenix

City of Hope, a world-renowned independent cancer research and treatment center, and its affiliate, Translational Genomics Research Institute (TGen), have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered.

2 Nov 2018

Study shows how machinery within immune system activates T cells to attack cancer

In just a few years, CAR T-cell and other adoptive T-cell therapies have emerged as among the most promising forms of cancer immunotherapy.

31 Oct 2018

CAR T cell News and Research

EMA recognizes the value of EBMT patient registry for novel CAR T-cell therapies

Moffitt researchers shed light on how CAR T cells function mechanistically

New mouse model replicates development and progression of Type I diabetes

NETRF announces $2.5 million funding for neuroendocrine cancer research

UCLA researchers demonstrate new technique to develop cancer-fighting T cells

Quanterix extends oncology footprint with accelerated launch of next gen SP-X platform and CorPlex validated 10-Plex

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Physician-scientists present updated efficacy data on CAR T-cell gene immunotherapy

CAR-T cell therapy appears to be promising option for treating large B-cell lymphoma

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

New strategies may improve performance of CAR-T cell therapy in treating cancer

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

First-ever European Meeting on CAR T Cell Therapy represents educational opportunity for healthcare professionals

New study sheds light on how CAR T cell therapy works

TGen and City of Hope announce letter of intent to develop new cell therapy manufacturing facility

Cytek Biosciences introduces new Northern Lights series of advanced flow cytometry systems

TGen, City of Hope to develop cell therapy manufacturing facility in Phoenix

Study shows how machinery within immune system activates T cells to attack cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News